首页 > 市场调查报告书 > 製药

癌症

欧洲胶质瘤治疗市场预测至 2030 年 - 区域分析 - 按疾病、治疗类型、等级和最终用户

市场调查报告书

商品编码

1452586

欧洲胶质瘤治疗市场预测至 2030 年 - 区域分析 - 按疾病、治疗类型、等级和最终用户

Europe Glioma Treatment Market Forecast to 2030 - Regional Analysis - by Disease, Treatment Type, Grade, and End User

出版日期: 2024年01月15日 | 出版商:

The Insight Partners | 英文 96 Pages | 订单完成后即时交付

价格

简介目录图表

欧洲神经胶质瘤治疗市场预计将从2022年的9.5999亿美元成长到2030年的19.051亿美元。预计2022年至2030年CAGR为8.9%。

高恶性度胶质瘤盛行率的增加推动了欧洲胶质瘤治疗市场

高恶性度神经胶质瘤包括侵袭性脑瘤，如胶质母细胞瘤、间变性星状细胞瘤和少突胶质细胞瘤。这些肿瘤的特征是快速生长、侵袭行为和对常规治疗方法的抵抗。高恶性度胶质瘤是一种尚未完全了解的多方面肿瘤，这是其发生率增加的主要原因。此外，人口老化、环境暴露、遗传倾向和诊断能力的提高是导致大量病例的其他显着因素。胶质瘤，特别是胶质母细胞瘤，因其位于大脑内且能够破坏关键神经功能而对患者的生活造成毁灭性影响而闻名。

最常见且最危险的脑肿瘤类型是胶质母细胞瘤。在全球范围内，每年发现超过 25 万例新发原发性恶性脑肿瘤病例，其中胶质瘤占其中的 77%。它仍然是一种罕见疾病，占原发性恶性脑肿瘤的 50% 以上。

欧洲神经胶质瘤治疗市场概述

欧洲的欧洲神经胶质瘤治疗市场分为法国、德国、义大利、西班牙、英国和欧洲其他地区。该地区在全球市场中占有第二大份额，这可归因于脑肿瘤病例数量的增加、法国脑肿瘤治疗技术的进步、英国神经系统疾病盛行率的增加以及英国医疗保健投资的激增。德国。英国的医疗保健部门拥有发达的先进医疗技术和设备。根据英国国家卫生服务中心统计，英国每年有超过11,000人被诊断出患有脑肿瘤，其中近50%的肿瘤是癌性的。根据 Globocan 2020资料，英国记录了约 7,697 例新发脑癌和中枢神经系统癌症病例。由于发病率迅速上升，一些私人和政府组织正在投资癌症研究。根据英国癌症研究中心(BCCR0001) 于2021 年4 月发布的与脑肿瘤和儿童癌症研究相关的书面证据，英国癌症研究中心自2018 年以来已承诺投入3545 万美元，透过资助脑肿瘤研究和启动脑肿瘤研究来鼓励脑肿瘤研究。卓越中心和辐射研究网络。该中心在2019-2020年投资1,520万美元用于脑肿瘤研究，并在2019-2020年投资1,112万美元用于影响儿童和青少年的癌症研究，成为英国脑肿瘤领域最大的研究资助者之一。

欧洲胶质瘤治疗市场收入及 2030 年预测（百万美元）

欧洲神经胶质瘤治疗市场细分

欧洲神经胶质瘤治疗市场按疾病、治疗类型、等级、最终用户和国家细分。

根据疾病，欧洲神经胶质瘤治疗市场分为星状细胞瘤、少突星状细胞瘤和少突胶质细胞瘤。 2022 年，星状细胞瘤细分市场占据欧洲神经胶质瘤治疗市场的最大份额。

依治疗类型，欧洲胶质瘤治疗市场分为手术、化疗、放射治疗等。 2022年，手术细分市场在欧洲神经胶质瘤治疗市场中占最大份额。

根据级别，欧洲神经胶质瘤治疗市场分为低级别和高级别。 2022 年，高层级细分市场在欧洲神经胶质瘤治疗市场中占有更大份额。

根据最终用户，欧洲神经胶质瘤治疗市场分为医院和诊所以及门诊手术中心。 2022 年，医院和诊所细分市场在欧洲神经胶质瘤治疗市场中占有更大份额。

根据国家/地区，欧洲神经胶质瘤治疗市场分为法国、德国、义大利、西班牙、英国和欧洲其他地区。 2022 年，德国在欧洲神经胶质瘤治疗市场占据主导地位。

Amgen Inc、Amneal Pharmaceuticals Inc、Biocon Ltd、F. Hoffmann-La Roche Ltd、Karyopharm Therapeutics Inc、Merck & Co Inc、Pfizer Inc、Sun Pharmaceutical Industries Ltd 和 Teva Pharmaceutical Industries Ltd 是在欧洲运营的一些领先公司神经胶质瘤治疗市场。

High-grade gliomas include aggressive brain tumors such as glioblastomas, anaplastic astrocytomas, and oligodendrogliomas. These tumors are characterized by their rapid growth, infiltrative behavior, and resistance to conventional treatment methods. High-grade gliomas are multifaceted tumors that are not yet fully understood, which is a major reason for their increasing incidence. Moreover, aging populations, environmental exposure, genetic predispositions, and improved diagnostic capabilities are other notable factors that result in a large number of cases. Gliomas, particularly glioblastomas, are known for their devastating impact on patients\' lives due to their location within the brain and ability to disrupt critical neurological functions.

The most frequent and dangerous type of brain tumor is glioblastoma. Globally, more than 250,000 new cases of primary malignant brain tumors are detected each year, with gliomas accounting for 77% of these occurrences. It still remains a rare disease, accounting for over 50% of primary malignant brain tumors.

Europe Glioma Treatment Market Overview

The Europe glioma treatment market in Europe is segmented into France, Germany, Italy, Spain, the UK, and the Rest of Europe. The region holds the second-largest share of the global market, which can be attributed to the increasing number of brain tumor cases, technological advancements in brain tumor treatments in France, the increasing prevalence of neurological disorders in the UK, and surging healthcare investments in Germany. The healthcare sector in the UK has access to well-developed advanced medical technologies and devices. According to the United Kingdom National Health Service, more than 11,000 people are diagnosed with brain tumors in the UK each year, of which nearly 50% of tumors are cancerous. Per the Globocan 2020 data, the UK recorded about 7,697 new cases of brain and central nervous system cancer. As a result of the burgeoning incidence, several private and government organizations are investing in cancer research. As per the written evidence related to brain tumor and childhood cancer research from Cancer Research UK (BCCR0001), released in April 2021, Cancer Research UK has committed USD 35.45 million since 2018 to encourage brain tumor research through funding calls for brain tumor research and launching centers of excellence and a radiation research network. The center invested USD15.20 million in brain tumor research, and USD 11.12 million in cancer research affecting children and adolescents in 2019-2020 to become one of the largest research funders in the field of brain tumors across the UK.

Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Million)

Europe Glioma Treatment Market Segmentation

The Europe glioma treatment market is segmented into disease, treatment type, grade, end user, and country.

Based on disease, the Europe glioma treatment market is segmented into astrocytoma, oligoastrocytoma, and oligodendroglioma. The astrocytoma segment held the largest share of the Europe glioma treatment market in 2022.

Based on treatment type, the Europe glioma treatment market is segmented into surgery, chemotherapy, radiation therapy, and others. The surgery segment held the largest share of the Europe glioma treatment market in 2022.

Based on grade, the Europe glioma treatment market is segmented into low grade and high grade. The high grade segment held a larger share of the Europe glioma treatment market in 2022.

Based on end user, the Europe glioma treatment market is segmented into hospital & clinics and ambulatory surgical center. The hospital & clinics segment held a larger share of the Europe glioma treatment market in 2022.

Based on country, the Europe glioma treatment market is segmented into France, Germany, Italy, Spain, the UK, and the Rest of Europe. Germany dominated the Europe glioma treatment market in 2022.

Amgen Inc, Amneal Pharmaceuticals Inc, Biocon Ltd, F. Hoffmann-La Roche Ltd, Karyopharm Therapeutics Inc, Merck & Co Inc, Pfizer Inc, Sun Pharmaceutical Industries Ltd, and Teva Pharmaceutical Industries Ltd are some of the leading companies operating in the Europe glioma treatment market.

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Europe Glioma Treatment Market - Key Industry Dynamics

4.1 Market Drivers
- 4.1.1 Government Funding for Glioma Treatment
- 4.1.2 Increase in Prevalence of High-Grade Glioma
4.2 Key Market Restraints
- 4.2.1 High Cost of Diagnosis
4.3 Key Market Opportunities
- 4.3.1 Advancements in Healthcare Sector in Emerging Economies
4.4 Future Trends
- 4.4.1 Surge in Drug Approvals for Glioma Treatment
4.5 Impact Analysis:

5. Glioma Treatment Market - Europe Market Analysis

5.1 Europe Glioma Treatment Market Revenue (US$ Mn), 2022 - 2030

6. Europe Glioma Treatment Market - Revenue and Forecast to 2030 - by Disease

6.1 Overview
6.2 Europe Glioma Treatment Market Revenue Share, by Disease 2022 & 2030 (%)
6.3 Astrocytoma
- 6.3.1 Overview
- 6.3.2 Astrocytoma: Europe Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
6.4 Oligoastrocytoma
- 6.4.1 Overview
- 6.4.2 Oligoastrocytoma: Europe Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
6.5 Oligodendroglioma
- 6.5.1 Overview
- 6.5.2 Oligodendroglioma: Europe Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)

7. Europe Glioma Treatment Market - Revenue and Forecast to 2030 - by Treatment Type

7.1 Overview
7.2 Europe Glioma Treatment Market Revenue Share, by Treatment Type 2022 & 2030 (%)
7.3 Surgery
- 7.3.1 Overview
- 7.3.2 Surgery: Europe Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Chemotherapy
- 7.4.1 Overview
- 7.4.2 Chemotherapy: Europe Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
7.5 Radiation Therapy
- 7.5.1 Overview
- 7.5.2 Radiation Therapy: Europe Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
7.6 Others
- 7.6.1 Overview
- 7.6.2 Others: Europe Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)

8. Europe Glioma Treatment Market - Revenue and Forecast to 2030 - by Grade

8.1 Overview
8.2 Europe Glioma Treatment Market Revenue Share, by Grade 2022 & 2030 (%)
8.3 Low Grade
- 8.3.1 Overview
- 8.3.2 Low Grade: Europe Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  - 8.3.2.1 Grade I: Europe Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  - 8.3.2.2 Grade II: Europe Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
8.4 High Grade
- 8.4.1 Overview
- 8.4.2 High Grade: Europe Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  - 8.4.2.1 Grade III: Europe Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  - 8.4.2.2 Grade IV: Europe Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)

9. Europe Glioma Treatment Market - Revenue and Forecast to 2030 - by End User

9.1 Overview
9.2 Europe Glioma Treatment Market Revenue Share, by End User 2022 & 2030 (%)
9.3 Hospital & Clinics
- 9.3.1 Overview
- 9.3.2 Hospital & Clinics: Europe Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
9.4 Ambulatory Surgical Centers
- 9.4.1 Overview
- 9.4.2 Ambulatory Surgical Centers: Europe Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)

10. Europe Glioma Treatment Market - Country Analysis

10.1 Overview
- 10.1.1 Europe Glioma Treatment Market, by Country
  - 10.1.1.1 UK
    - 10.1.1.1.1 UK: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.1.1.1.2 UK: Europe Glioma Treatment Market, by Disease
    - 10.1.1.1.3 UK: Europe Glioma Treatment Market, by Treatment Type
    - 10.1.1.1.4 UK: Europe Glioma Treatment Market, by Grade
    - 10.1.1.1.4.1 UK: Europe Glioma Treatment Market, by Low Grade
    - 10.1.1.1.4.2 UK: Europe Glioma Treatment Market, by High Grade
    - 10.1.1.1.5 UK: Europe Glioma Treatment Market, by End User
  - 10.1.1.2 Germany
    - 10.1.1.2.1 Germany: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.1.1.2.2 Germany: Europe Glioma Treatment Market, by Disease
    - 10.1.1.2.3 Germany: Europe Glioma Treatment Market, by Treatment Type
    - 10.1.1.2.4 Germany: Europe Glioma Treatment Market, by Grade
    - 10.1.1.2.4.1 Germany: Europe Glioma Treatment Market, by Low Grade
    - 10.1.1.2.4.2 Germany: Europe Glioma Treatment Market, by High Grade
    - 10.1.1.2.5 Germany: Europe Glioma Treatment Market, by End User
  - 10.1.1.3 France
    - 10.1.1.3.1 France: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.1.1.3.2 France: Europe Glioma Treatment Market, by Disease
    - 10.1.1.3.3 France: Europe Glioma Treatment Market, by Treatment Type
    - 10.1.1.3.4 France: Europe Glioma Treatment Market, by Grade
    - 10.1.1.3.4.1 France: Europe Glioma Treatment Market, by Low Grade
    - 10.1.1.3.4.2 France: Europe Glioma Treatment Market, by High Grade
    - 10.1.1.3.5 France: Europe Glioma Treatment Market, by End User
  - 10.1.1.4 Italy
    - 10.1.1.4.1 Italy: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.1.1.4.2 Italy: Europe Glioma Treatment Market, by Disease
    - 10.1.1.4.3 Italy: Europe Glioma Treatment Market, by Treatment Type
    - 10.1.1.4.4 Italy: Europe Glioma Treatment Market, by Grade
    - 10.1.1.4.4.1 Italy: Europe Glioma Treatment Market, by Low Grade
    - 10.1.1.4.4.2 Italy: Europe Glioma Treatment Market, by High Grade
    - 10.1.1.4.5 Italy: Europe Glioma Treatment Market, by End User
  - 10.1.1.5 Spain
    - 10.1.1.5.1 Spain: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.1.1.5.2 Spain: Europe Glioma Treatment Market, by Disease
    - 10.1.1.5.3 Spain: Europe Glioma Treatment Market, by Treatment Type
    - 10.1.1.5.4 Spain: Europe Glioma Treatment Market, by Grade
    - 10.1.1.5.4.1 Spain: Europe Glioma Treatment Market, by Low Grade
    - 10.1.1.5.4.2 Spain: Europe Glioma Treatment Market, by High Grade
    - 10.1.1.5.5 Spain: Europe Glioma Treatment Market, by End User
  - 10.1.1.6 Rest of Europe
    - 10.1.1.6.1 Rest of Europe: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.1.1.6.2 Rest of Europe: Europe Glioma Treatment Market, by Disease
    - 10.1.1.6.3 Rest of Europe: Europe Glioma Treatment Market, by Treatment Type
    - 10.1.1.6.4 Rest of Europe: Europe Glioma Treatment Market, by Grade
    - 10.1.1.6.4.1 Rest of Europe: Europe Glioma Treatment Market, by Low Grade
    - 10.1.1.6.4.2 Rest of Europe: Europe Glioma Treatment Market, by High Grade
    - 10.1.1.6.5 Rest of Europe: Europe Glioma Treatment Market, by End User

11. Europe Glioma Treatment Market Industry Landscape

11.1 Overview
11.2 Growth Strategies Done by the Companies in the Market, (%)
11.3 Organic Developments
- 11.3.1 Overview
11.4 Inorganic Developments
- 11.4.1 Overview

12. Company Profiles

12.1 F. Hoffmann-La Roche Ltd
- 12.1.1 Key Facts
- 12.1.2 Business Description
- 12.1.3 Products and Services
- 12.1.4 Financial Overview
- 12.1.5 SWOT Analysis
- 12.1.6 Key Developments
12.2 Sun Pharmaceutical Industries Ltd
- 12.2.1 Key Facts
- 12.2.2 Business Description
- 12.2.3 Products and Services
- 12.2.4 Financial Overview
- 12.2.5 SWOT Analysis
- 12.2.6 Key Developments
12.3 Amgen Inc
- 12.3.1 Key Facts
- 12.3.2 Business Description
- 12.3.3 Products and Services
- 12.3.4 Financial Overview
- 12.3.5 SWOT Analysis
- 12.3.6 Key Developments
12.4 Teva Pharmaceutical Industries Ltd
- 12.4.1 Key Facts
- 12.4.2 Business Description
- 12.4.3 Products and Services
- 12.4.4 Financial Overview
- 12.4.5 SWOT Analysis
- 12.4.6 Key Developments
12.5 Pfizer Inc
- 12.5.1 Key Facts
- 12.5.2 Business Description
- 12.5.3 Products and Services
- 12.5.4 Financial Overview
- 12.5.5 SWOT Analysis
- 12.5.6 Key Developments
12.6 Amneal Pharmaceuticals Inc
- 12.6.1 Key Facts
- 12.6.2 Business Description
- 12.6.3 Products and Services
- 12.6.4 Financial Overview
- 12.6.5 SWOT Analysis
- 12.6.6 Key Developments
12.7 Karyopharm Therapeutics Inc
- 12.7.1 Key Facts
- 12.7.2 Business Description
- 12.7.3 Products and Services
- 12.7.4 Financial Overview
- 12.7.5 SWOT Analysis
- 12.7.6 Key Developments
12.8 Biocon Ltd
- 12.8.1 Key Facts
- 12.8.2 Business Description
- 12.8.3 Products and Services
- 12.8.4 Financial Overview
- 12.8.5 SWOT Analysis
- 12.8.6 Key Developments

13. Appendix

13.1 About Us
13.2 Glossary of Terms

简介目录图表

List Of Tables

Table 1. Europe Glioma Treatment Market Segmentation
Table 2. UK: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) - Disease
Table 3. UK: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) - Treatment Type
Table 4. UK: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -Grade
Table 5. UK: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -Low Grade
Table 6. UK: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -High Grade
Table 7. UK: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) - End User
Table 8. Germany: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) - Disease
Table 9. Germany: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) - Treatment Type
Table 10. Germany: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -Grade
Table 11. Germany: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -Low Grade
Table 12. Germany: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -High Grade
Table 13. Germany: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) - End User
Table 14. France: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) - Disease
Table 15. France: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) - Treatment Type
Table 16. France: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -Grade
Table 17. France: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -Low Grade
Table 18. France: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -High Grade
Table 19. France: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) - End User
Table 20. Italy: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) - Disease
Table 21. Italy: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) - Treatment Type
Table 22. Italy: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -Grade
Table 23. Italy: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -Low Grade
Table 24. Italy: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -High Grade
Table 25. Italy: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) - End User
Table 26. Spain: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) - Disease
Table 27. Spain: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) - Treatment Type
Table 28. Spain: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -Grade
Table 29. Spain: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -Low Grade
Table 30. Spain: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -High Grade
Table 31. Spain: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) - End User
Table 32. Rest of Europe: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) - Disease
Table 33. Rest of Europe: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) - Treatment Type
Table 34. Rest of Europe: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -Grade
Table 35. Rest of Europe: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -Low Grade
Table 36. Rest of Europe: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -High Grade
Table 37. Rest of Europe: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) - End User
Table 38. Organic Developments Done By Companies
Table 39. Inorganic Developments Done By Companies
Table 40. Glossary of Terms, Europe glioma treatment market

List Of Figures

Figure 1. Europe Glioma Treatment Market Segmentation, By Country
Figure 2. Europe Glioma Treatment Market - Key Industry Dynamics
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. Europe Glioma Treatment Market Revenue (US$ Mn), 2022 - 2030
Figure 5. Europe Glioma Treatment Market Revenue Share, by Disease 2022 & 2030 (%)
Figure 6. Astrocytoma: Europe Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
Figure 7. Oligodendroglioma: Europe Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
Figure 8. Oligodendroglioma: Europe Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
Figure 9. Europe Glioma Treatment Market Revenue Share, by Treatment Type 2022 & 2030 (%)
Figure 10. Surgery: Europe Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
Figure 11. Chemotherapy: Europe Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
Figure 12. Radiation Therapy: Europe Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
Figure 13. Others: Europe Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
Figure 14. Europe Glioma Treatment Market Revenue Share, by Grade 2022 & 2030 (%)
Figure 15. Low Grade: Europe Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
Figure 16. Grade I: Europe Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
Figure 17. Grade II: Europe Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
Figure 18. High Grade: Europe Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
Figure 19. Grade III: Europe Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
Figure 20. Grade IV: Europe Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
Figure 21. Europe Glioma Treatment Market Revenue Share, by End User 2022 & 2030 (%)
Figure 22. Hospital & Clinics: Europe Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
Figure 23. Ambulatory Surgical Centers: Europe Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
Figure 24. Europe Glioma Treatment Market, By Country, 2022 ($Mn)
Figure 25. Europe Glioma Treatment Market, By Key Countries, 2022 And 2030 (%)
Figure 26. UK: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 27. Germany: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 28. France: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 29. Italy: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 30. Spain: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 31. Rest of Europe: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 32. Growth Strategies Done by the Companies in the Market, (%)